<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200413047056N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-01-28</date_registration>
      <primary_sponsor>Birjand University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of pethidine and bupivacaine in spinal anesthesia</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of intrathecal injection of pethidine, pethidine-bupivacaine and bupivacaine on pain severity and hemodynamic parameters after elective cesarean section</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-01-31</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/53865</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research, Randomization description: In this research, a simple randomization method will be used. In this way 90 sealed envelopes, each containing a card of a different color and each color representing a group, will be placed in a box. After entering the operating room, if the patient has the inclusion criteria, she will pull one envelope out of the box and will be placed in the desired group according to the color of the card inside, Blinding description: In this double-blind clinical study, 90 sealed envelopes, each containing a card of a different color and each color representing a group, will be placed in a box. After entering the operating room, if the patient has the inclusion criteria, she will pull one envelope out of the box and will be placed in the desired group according to the color of the card inside, and then the drug will be prepared by an independent researcher (anesthesia technician).</study_design>
      <phase>1-2</phase>
      <hc_freetext>The rate of analgesia in cesarean section.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Healthy pregnant women 20 to 40 years old undergoing spinal anesthesia with pethidine. After prepping and draping, spinal anesthesia with 100mg of pethidine will be performed using a 25 G Quincke needle in the L4-L5 or L5-S1 intervertebral space in a sitting position. After the injection, the patient is immediately returned to the supine position, and standard monitoring including continuous pulse oximetry and ECG will be used. Intervention 2: Intervention group 2: Healthy pregnant women 20 to 40 years old undergoing spinal anesthesia with bupivacaine. After prepping and draping, spinal anesthesia with 10mg of bupivacaine will be performed using a 25 G Quincke needle in the L4-L5 or L5-S1 intervertebral space in a sitting position. After the injection, the patient is immediately returned to the supine position, and standard monitoring including continuous pulse oximetry and ECG will be used. Intervention 3: Intervention group 3: Healthy pregnant women 20 to 40 years old undergoing spinal anesthesia with the pethidine-bupivacaine mixture. After prepping and draping, spinal anesthesia with 50mg of pethidine and 5mg of bupivacaine will be performed using a 25 G Quincke needle in the L4-L5 or L5-S1 intervertebral space in a sitting position. After the injection, the patient is immediately returned to the supine position, and standard monitoring including continuous pulse oximetry and ECG will be used.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Total data after unidentifiable individuals

When:
One year after the results are published

To whom:
every one

Conditions:
For research

Where to obtain:
By Email with corresponding

How to obtain:
About a week

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maliheh Zangoue</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ghaffari Ave</address>
        <city>Birjand</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۹۷۱۷۸۵۳۵۷۷</zip>
        <telephone>+98 56 3239 5000</telephone>
        <email>Mzangoue@yahoo.com</email>
        <affiliation>Birjand University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Amirs Saber Tanha</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ghaffari Ave</address>
        <city>Birjand</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۹۷۱۷۸۵۳۵۷۷</zip>
        <telephone>+98 56 3239 5000</telephone>
        <email>amirsaber63@gmail.com</email>
        <affiliation>Birjand University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>ASA 1 and ASA 2 (patients with healthy or controlled mild disease) in the range of 20 to 40 years
No drug and smoking addiction
No history of hypertension, diabetes and uncontrolled comorbidities
Elective cesarean section
No chronic pain
No mental disorder and hysteria</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Emergency cesarean section
Placental abruption
Placental accreta
Severe bleeding during surgery
Drug and smoking addiction
Uncontrolled comorbidities
Take painkillers or antiemetics 24 hours before operation
Skin infection at the site of lumbar injection
History of bupivacaine or pethidine allergy
Change ofanesthesia  type during the operation
Blood transfusion during the operation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O74.6</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other complications of spinal and epidural anesthesia during labor and delivery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Healthy pregnant women 20 to 40 years old undergoing spinal anesthesia with pethidine. After prepping and draping, spinal anesthesia with 100mg of pethidine will be performed using a 25 G Quincke needle in the L4-L5 or L5-S1 intervertebral space in a sitting position. After the injection, the patient is immediately returned to the supine position, and standard monitoring including continuous pulse oximetry and ECG will be used.</i_keyword>
      <i_keyword>Intervention group 2: Healthy pregnant women 20 to 40 years old undergoing spinal anesthesia with bupivacaine. After prepping and draping, spinal anesthesia with 10mg of bupivacaine will be performed using a 25 G Quincke needle in the L4-L5 or L5-S1 intervertebral space in a sitting position. After the injection, the patient is immediately returned to the supine position, and standard monitoring including continuous pulse oximetry and ECG will be used.</i_keyword>
      <i_keyword>Intervention group 3: Healthy pregnant women 20 to 40 years old undergoing spinal anesthesia with the pethidine-bupivacaine mixture. After prepping and draping, spinal anesthesia with 50mg of pethidine and 5mg of bupivacaine will be performed using a 25 G Quincke needle in the L4-L5 or L5-S1 intervertebral space in a sitting position. After the injection, the patient is immediately returned to the supine position, and standard monitoring including continuous pulse oximetry and ECG will be used.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain. Timepoint: Within 24 hours after the intervention. Method of measurement: Number of suppositories consumed.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Birjand University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-07-23</approval_date>
        <contact_name>Ethics committee of Birjand University of Medical Sciences</contact_name>
        <contact_address>Ghaffari Ave Birjand South Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
